dezocine and Pain--Postoperative

As the adjunctive anesthesia to propofol, both dezocine and fentanyl showed some potential for gastrointestinal endoscopy. This meta-analysis aimed to compare their efficacy and safety.. PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched. Randomized controlled trials (RCTs) assessing the effect of dezocine versus fentanyl for the anesthesia of patients undergoing gastrointestinal endoscopy were included.. Five RCTs involving 677 patients were included in the meta-analysis. Overall, compared with fentanyl plus propofol for gastrointestinal endoscopy, dezocine plus propofol resulted in the reduction in propofol dose(mean difference [MD] = -11.72; 95% confidence interval [CI] = -22.83 to -0.61; P = .04), awakening time (std. MD = -1.79; 95% CI = -3.31 to -0.27; P = .02) and hypopnea (risk ratio [RR] = 0.16; 95% CI = 0.06-0.41; P = .0002), but had no remarkable effect on induction time (MD = 1.20; 95% CI = -0.98 to 3.39; P = .28), postoperative pain score (MD = -0.38; 95% CI = -1.00 to 0.24; P = .24), nausea or vomiting (RR = 0.45; 95% CI = 0.10-1.98; P = .29).. Dezocine plus propofol may be better for the anesthesia of gastrointestinal endoscopy than fentanyl plus propofol.

Topics: Adult; Aged; Analgesics, Opioid; Anesthetics, Intravenous; Bridged Bicyclo Compounds, Heterocyclic; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Fentanyl; Humans; Male; Middle Aged; Pain, Postoperative; Propofol; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes; Treatment Outcome

Dezocine is considered to be an alternative medication for managing postoperative pain. The aim of this study was to assess the efficacy and safety of this drug in this regard.. Medline, EMBASE and the Cochrane Central Register of Control Trials (CENTRAL) were searched to identify all randomized controlled trials (RCTs) that compare dezocine with placebo or dezocine with morphine on postoperative pain. The data were extracted and pooled using Mantel-Haenszel random effects model. Heterogeneity was tested using the I2 statistic with values >50% and Chi2 test with P ≤ 0.05 indicating obvious heterogeneity between the studies.. Seven trials evaluating 665 patients were included. The number of patients with at least 50% pain relief was increased (N = 234; RR 3.04, 95% CI 2.27 to 4.08) and physician (N = 465; RR 2.84, 95% CI 1.66 to 4.84) and patient satisfaction (N = 390; RR 2.81, 95% CI 1.85 to 4.26) were improved following the administration of dezocine compared with the placebo. The effects of dezocine were similar to those of morphine in terms of the number of patients reporting at least 50% pain relief within 2-6 h after surgery (N = 235; RR 1.29, 95% CI 1.15 to 1.46) and physician (N = 234; RR 1.18, 95% CI 0.93 to 1.49) and patient (N = 158; RR 1.33, 95% CI 0.93 to 1.92) satisfaction. While, the number of patients with at least 50% pain relief within 0-1 h after surgery increased following dezocine compared with morphine treatment (N = 79; RR 1.45, 95% CI 1.18 to 1.77). There was no difference in the incidence of postoperative nausea and vomiting (PONV) following dezocine treatment compared with the placebo (N = 391; RR 1.06, 95% CI 0.42 to 2.68) or morphine treatment (N = 235; RR 0.65, 95% CI 0.14 to 2.93).. Dezocine is a promising analgesic for preventing postoperative pain, but further studies are required to evaluate its safety.

Topics: Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Humans; Morphine; Pain Management; Pain, Postoperative; Patient Satisfaction; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes

A total of 130 patients who underwent percutaneous testicular sperm aspiration from March 2021 to February 2023 were randomly divided into a Dezocine group and a control group. The Dezocine group received a muscle injection of 0.05mg/kg Dezocine 30 minutes before surgery, while the control group received a muscle injection of 0.01ml/kg normal saline. Both groups received 3ml of 2% lidocaine for spermatic cord block anesthesia. The anesthesia onset time, anesthesia duration, numeric rating scale (NRS) score, anesthesia satisfaction rate and incidence of adverse reactions were recorded and compared between the two groups. The statistical results showed that there were significant differences between the two groups in terms of anesthesia onset time, anesthesia duration, anesthesia satisfaction rate, non-steroidal anti-inflammatory drug (NSAID) use within 24 hours after surgery and NRS scores at 15 minutes, 1 hour and 2 hours after surgery. The incidence of adverse reactions in the Dezocine group was lower than that in the control group, but the difference was not statistically significant. The combination of Dezocine and lidocaine for spermatic cord block anesthesia during percutaneous testicular sperm aspiration is safe, effective and associated with fewer adverse reactions. It is suitable for clinical application and promotion in reproductive medicine outpatient surgery.

Topics: Analgesics, Opioid; Anesthesia, Local; Humans; Lidocaine; Male; Pain, Postoperative; Semen; Sperm Retrieval

The optimal analgesic strategy for surgical pain after lobectomy remains undefined. To compare the combination of flurbiprofen axetil and dezocine with flurbiprofen axetil alone and dezocine alone, in post-lobectomy patients.. A single-center, parallel-design double-blind superiority trial, with 5 groups (1:1:1:1:1 ratio) with different combinations of flurbiprofen and dezocine. Patients scheduled for lobectomy will be recruited. The primary outcome is total sufentanil use in patient-controlled intravenous analgesia within the first 24 postoperative hours. Secondary outcomes include pain numeric rating scales at 6th, 12th, 24th, 48th, and 72th postoperative hours, and on the 1st, 3rd, and 6th postoperative months at rest and during coughing, adverse effects from experimental drug treatment, sufentanil use at other time points, analgesia cost, time to chest tube removal, length of hospital stay, time to pass first flatus, and serum level of cytokines. Doctors, patients, and nurses are blinded, and only the manager is unblinded. Analysis is intention-to-treat. Statistical analysis is pre-specified. Statistical comparison of the treatment groups includes one-way analysis of variance followed by Tukey's post hoc test.. Trial did not begin to recruit. Participant recruitment start date is planned to be June 1, 2020. Approximate recruitment end date is May 31, 2021. If successful, the trial may shed light on the use of certain analgesic combinations in post-lobectomy pain control.. Chinese Clinical Trial Registry ChiCTR1800018563 . Registered on September 25, 2018.

Topics: Analgesia, Patient-Controlled; Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Double-Blind Method; Flavin-Adenine Dinucleotide; Flurbiprofen; Humans; Pain, Postoperative; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes

There are no studies on the use of dexmedetomidine combined with sufentanil and dezocine-based patient-controlled intravenous analgesia (PCIA) in females undergoing thoracic surgery. We postulate that introducing dexmedetomidine to a combination of dezocine-based PCA drugs and sufentanil will increase female patients' global satisfaction degree.. One hundred fifty-two female patients with physical classification type I or II according to the American Society of Anesthesiologists undergoing thoracoscopic surgery were arbitrarily classified into two categories, either receiving sufentanil and dezocine-based PCIA (group C) or incorporating dexmedetomidine with sufentanil and dezocine-based PCIA (group D). The patients' global satisfaction degree, postoperative nausea and vomiting (PONV), PCA bolus, rescue analgesia requirements, drug-related adverse effects, rest and coughing visual analogue scale (VAS) ratings, and Ramsay sedation scores (RSS) were measured at 6, 12, 24, 36 and 48 h after surgery.. Compared with the C group, the patient satisfaction degree was significantly higher; pain scores at rest and coughing were significantly different at 6, 12, 24, 36 and 48 h postoperatively; less rescue analgesia and PCA bolus were required; and a lower incidence of PONV was found in the D group. There were non-significant trends for the sedation scores and drug-related adverse effects in both groups.. Dexmedetomidine combined with sufentanil and dezocine increased female patients' global satisfaction degree after thoracoscopic surgery. This effect could be linked to the improvement in postoperative analgesia and reduction in postoperative nausea and vomiting; the combined treatment did not increase drug-related adverse effects in female patients.. Chinese Clinical Trial Registry number, ChiCTR2000030429 . Registered on March 1, 2020.

Topics: Adult; Analgesia; Analgesia, Patient-Controlled; Analgesics, Non-Narcotic; Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Dexmedetomidine; Female; Humans; Middle Aged; Pain Management; Pain Measurement; Pain, Postoperative; Patient Satisfaction; Postoperative Period; Sufentanil; Tetrahydronaphthalenes; Thoracoscopy; Time Factors; Treatment Outcome; Visual Analog Scale

To evaluate the effect of dezocine on the postoperative ratio of Th1/Th2 cytokines in patients undergoing laparoscopic radical gastrectomy.. Sixty patients undergoing laparoscopic radical gastrectomy were randomly divided into two groups (n=30): dezocine group (Group D) and sufentanil group (Group S). They received patient-controlled intravenous analgesia (PCIA) after the operation with either dezocine 0.8 mg/kg (Group D) or sufentanil 2 µg/kg (Group S). Both groups also received ondansetron 8 mg diluted to 100 mL with saline. The primary outcome was the Th1/Th2 cytokines ratio at predetermined intervals, 30 min before the induction of general anaesthesia and 0, 12, 24 and 48 h after surgery. The secondary endpoints were patients' pain scores, measured on a visual analogue scale (VAS) at predetermined intervals (0, 12, 24 and 48 h after surgery), and side effects at follow-up 48 h after surgery.. The Th1/Th2 cytokines ratio in Group D was significantly higher than Group S (. Dezocine increases the ratio of Th1/Th2 cytokines, relieves postoperative pain and causes fewer side effects in patients undergoing laparoscopic radical gastrectomy.

Topics: Adult; Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Cytokines; Dose-Response Relationship, Drug; Female; Gastrectomy; Humans; Injections, Intravenous; Laparoscopy; Male; Middle Aged; Pain, Postoperative; Prospective Studies; Sufentanil; Tetrahydronaphthalenes

Postoperative depression is one of the most common mental disorders in patients undergoing cancer surgery and it often delays postoperative recovery. We investigated whether dezocine, an analgesic with inhibitory effect on the serotonin and norepinephrine reuptake, could relieve postoperative depressive symptoms in patients undergoing colorectal cancer surgery.. This randomized, controlled, single-center, double-blind trial was performed in the Second Affiliated Hospital of the Army Medical University. A total of 120 patients were randomly assigned to receive either sufentanil (1.3 μg/kg) with dezocine (1 mg/kg) (dezocine group; n = 60) or only sufentanil (2.3 μg/kg) (control group; n = 60) for patient-controlled intravenous analgesia after colorectal cancer surgery. The primary outcome was the Beck Depression Inventory score at 2 days after surgery. The secondary outcomes included the Beck Anxiety Inventory, sleep quality, and quality of recovery scores.. Compared with those in the control group, patients in the dezocine group had lower depression scores (7.3±3.4 vs. 9.9±3.5, mean difference 2.6, 95% CI: 1.4-3.9; P<0.001) at 2 days after surgery and better night sleep quality at the day of surgery (P = 0.010) and at 1 day after the surgery (P<0.001). No significant difference was found in other outcomes between the two groups.. Intravenous analgesia using dezocine can relieve postoperative depression symptoms and improve sleep quality in patients undergoing colorectal cancer surgery.

Topics: Administration, Intravenous; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; China; Colorectal Neoplasms; Depression; Digestive System Surgical Procedures; Double-Blind Method; Female; Humans; Male; Middle Aged; Pain, Postoperative; Postoperative Complications; Sufentanil; Tetrahydronaphthalenes; Treatment Outcome

The combination of dezocine and sufentanil is often used for postoperative analgesia in China and other areas, but the interaction of both two drugs is still unclear. The purpose of this study was to evaluate the interaction of the analgesic effects of dezocine and sufentanil in the patients after gynecological laparoscopic surgery.. We conducted a prospective, randomized, double-blinded clinical trial. A total of 150 patients were divided into 5 groups (30 in each group) in the post-anesthesia care unit, namely, dezocine group (Group D), sufentanil group (Group S) and dezocine mixed sufentanil groups (Group DS1-3). In group D and S, the initial dose of dezocine or sufentanil was 5mg and 5μg intravenously, respectively. In Group DS1, the initial dose was dezocine 5mg × 3/4 and sufentanil 5μg × 1/4. In Group DS2, the initial dose was dezocine 5mg × 1/2 and sufentanil 5μg × 1/2. In Group DS3, the initial dose was dezocine 5mg × 1/4 and sufentanil 5μg × 3/4.. The median effective dose (ED50) of dezocine and sufentanil alone was 3.92 (95% confidence interval (CI) 3.01~4.64) mg and 3.71 (95% CI 2.78~4.39) μg, respectively. The isobolographic analysis showed that the combination of dezocine and sufentanil at 1:3, 1:1 or 3:1 appeared in the additive line.. In conclusion, when simultaneously administered intravenously, combined dezocine and sufentanil produce an additive effect for relieving the acute nociception after gynecological laparoscopic surgery.

Topics: Adult; Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Double-Blind Method; Female; Humans; Male; Pain, Postoperative; Pilot Projects; Prospective Studies; Sufentanil; Tetrahydronaphthalenes; Treatment Outcome

Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Pain, Postoperative; Prospective Studies; Structure-Activity Relationship; Tetrahydronaphthalenes; Urinary Bladder; Urinary Catheterization; Young Adult

Dezocine is proposed as an adjunctive analgesic for postoperative pain control. This randomized, double-blind, controlled study aimed to investigate the effect of preoperative Dezocine therapy on postoperative pain following laparoscopic cholecystectomy as well as the underlying mechanisms.Eighty patients scheduled for laparoscopic cholecystectomy were randomly allocated into 2 groups as follows: patients in Group D received Dezocine 0.15 mg/kg before anesthesia induction and patients in Group S received same volume of saline. The pain intensity, sedation score, sufentanil-based patient-controlled analgesia (PCA) consumption were recorded for 24 hours after surgery. Plasma concentrations of norepinephrine and serotonin were also measured.During the first 24 hours after surgery, the patients in Group D experienced lower pain score assessed by numerical rating scale (NRS) at 3 hours (rest: P = .038; movement: P = .036), 6 hours (rest: P = .038; movement: P = .036), 12 hours (rest: P = .038; movement: P = .036), and 24 hours (rest: P = .038; movement: P = .036). Dezocine also decreased the sedation levels at 5 minutes (P = .031) after arrival at the PACU. Sufentanil-based PCA consumption in Group D was decreased when compared with Group S in the second to fourth phase after surgery (6-12 hours: P = .017; 12-18 hours: P = .003; 18-24 hours: P = .039). Plasma norepinephrine and serotonin concentrations were higher in the Group D at 24 hours after surgery (norepinephrine: P = .009, serotonin: P = .042). In addition, Group D showed less incidence of nausea/vomiting (P = .032) as well as a higher postoperative satisfaction score after surgery (P = .017).In conclusion, preemptive Dezocine administration is suggested to be useful for the management of postoperative pain in short-lasting surgery such as laparoscopic cholecystectomy.

Topics: Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Cholecystectomy, Laparoscopic; Double-Blind Method; Drug Monitoring; Female; Humans; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Tetrahydronaphthalenes; Treatment Outcome

This study was performed to investigate the analgesic effects of intramuscular injection of dezocine-based local anesthesia in patients undergoing inguinal hernia repair.. A total of 120 patients underwent local herniorrhaphy from July 2015 to December 2016 and were randomly divided into 2 groups: the dezocine group, in which a preoperative intramuscular injection of dezocine was administered, and the control group, in which no dezocine injection was administered. The patients' pain and comfort levels were evaluated at 30 minutes, 2 hours, 6 hours, 12 hours, and 24 hours postoperatively.. The visual analog scale scores at 30 minutes, 2 hours, 6 hours, 12 hours, and 24 hours were significantly lower in the dezocine than control group. In the Bruggemann comfort scale evaluation, patients who received dezocine injections showed significantly greater comfort than those in the control group at 30 minutes, 2 hours, 6 hours, 12 hours, and 24 hours. No adverse reactions occurred in the dezocine group.. Dezocine-based local anesthesia can attenuate postoperative pain and increase the comfort level during and after herniorrhaphy.

Topics: Adult; Aged; Aged, 80 and over; Analgesia; Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Case-Control Studies; Female; Follow-Up Studies; Hernia, Inguinal; Herniorrhaphy; Humans; Injections, Intramuscular; Male; Middle Aged; Pain, Postoperative; Prognosis; Tetrahydronaphthalenes; Young Adult

To compare the analgesic effects of patient-controlled intravenous analgesia (PCA) with hydromorphone and sufentanil after thoracic surgery on postoperative pulmonary complications (PPCs).. A total of 142 patients who were scheduled for thoracic surgery were randomly allocated to receive PCA with hydromorphone (group A: experimental group): hydromorphone 0.2 mg/kg + dezocine 0.5 mg/kg + ramosetron 0.6 mg diluted with normal saline to 200 mL; or with sufentanil (group B: control group): sufentanil 3.0μg/kg + dezocine 0.5 mg/kg + ramosetron 0.6 mg diluted with normal saline to 200 mL. The parameters of intravenous analgesia pump were set as background dose 4 ml/h, PCA dose 1 mL, locking time 15 min. Pain NRS (numerical rating scale), Ramsay sedation score, nausea or vomiting score were evaluated at 0 h, 6 h, 12 h, 24 h, 48 h after operation. The cases of PPCs (atelectasis, pulmonary infection, respiratory failure), CRP (C-reaction protein) and inflammatory cells (white cell count and percentage of neutrophils) and blood gas analysis at 12 h after operation, length of ICU and postoperative stay were recorded for each patient.. Data of 136 patients were analyzed. Compared with group B (4[IQR:2,2]), the pain NRS in group A (2[IQR:4,4]) was significantly lower at 6 h after operation (P = 0.000). The CRP in group A (69.79 ± 32.13 mg/L) were lower than group B (76.76 ± 43.42 mg/L) after operation, but the difference was not significant (P = 0.427). No difference of nausea or vomiting was found between group A (7.3%) and group B (5.8%) postoperatively (P = 0.999). The PPCs were happened in 11 patients in group A (16.2%) and 22 patients in group B (32.4%) and the difference between two groups was significant (P = 0.027). Seven patients in group A (10.3%) and eighteen patients in group B (26.5%) had clinical evidence of pneumonia and the difference between two groups was significant (P = 0.014). The length of ICU and postoperative stay in group A were 2.73 h and 1.82 days less than group B respectively but the differences were not significant (P = 0.234, P = 0.186 respectively).. Compared with sufentanil, hydromorphone may provide better postoperative analgesic effect with less pulmonary complications for patients undergoing thoracic surgery, and it may accelerate patients' rehabilitation.. Randomized Controlled Trials ChiCTR1800014282c . Registered 3 January 2018.

Topics: Adult; Analgesia, Patient-Controlled; Benzimidazoles; Blood Gas Analysis; Bridged Bicyclo Compounds, Heterocyclic; Double-Blind Method; Female; Humans; Hydromorphone; Intensive Care Units; Length of Stay; Lung Diseases; Male; Middle Aged; Pain, Postoperative; Postoperative Complications; Sufentanil; Tetrahydronaphthalenes; Thoracic Surgical Procedures

This paper was aimed to further analyze the concrete clinical efficacy of dezocine as an anesthetic for peritoneal gynecology operation and to offer a scientific guidance for future surgical treatments. This paper randomly selected 1000 peritoneal gynecology operation patients in 5 hospitals from January to December 2015 as research objects in the observation group, who were mainly applied with dezocine in operative anesthesia. By analyzing data of cases, it concluded efficacy characteristics of dezocine in various phases, and thus provide scientific guidance for future surgical treatments. Another 500 patients who were given with fentanyl as anesthetic in peritoneal gynecology operation were selected as research objects in the control group. We compared the two groups in aspects of index changes before and after operative anesthesia, VAS scores and haemodynamics changes in 2 hours of anesthesia. The results showed that, index changes occurred in both of groups after anesthesia, but patients in the observation group presented a more obvious efficacy with a significant difference (P<0.05). Besides, adverse reactions in both of groups during the operation were basically comparative, so there was no significant difference (P>0.05) or statistical value. This research demonstrated that dezocine, as an anaesthetic in gynecology operation, has a good therapeutic effect and value of wide application in clinical anesthesia.

Topics: Adult; Analgesics, Opioid; Anesthesia; Bridged Bicyclo Compounds, Heterocyclic; Fentanyl; Gynecologic Surgical Procedures; Hemodynamics; Humans; Pain Measurement; Pain, Postoperative; Tetrahydronaphthalenes; Young Adult

To evaluate the analgesic and sedative effectiveness of dezocine and midazolam in vitrectomy.. One hundred and sixty patients undergoing vitrectomy were randomized into four groups. The control group was given local anesthetic in retrobulbar nerve block only, while the other three groups received a single dose of 0.1 mg/kg dezocine or/and 0.05 mg/kg midazolam (groups D, M, DM), respectively, at 10 min before retrobulbar block. Mean arterial pressure (MAP), heart rate (HR), and oxygen saturation (SpO. Group DM showed a decrease in HR during T0-T4 compared to Tp (p < 0.001). The MAP of all groups decreased significantly at T0 compared to Tp (p < 0.05), but remained unchanged at T1-T4. At T2, all groups have lower pain level than control (p < 0.001), while group DM showed the lowest pain level. At T4, groups D and DM showed a lower pain level than control (p < 0.01). Groups M and DM showed a higher Ramsay score than group C (p < 0.01). Compared with control, group D had a higher PONV rate (p < 0.1). Groups M and DM showed a lower PONV rate than group D (p < 0.0001), and group M had a lower PONV rate than group C (p < 0.01).. Combinatory use of dezocine and midazolam in addition to local anesthetic in retrobulbar nerve block can help relief pain and anxiety during vitrectomy and reduce PONV.

Topics: Adult; Analgesics, Opioid; Anesthesia; Anesthetics, Intravenous; Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Dose-Response Relationship, Drug; Female; Humans; Intraoperative Period; Male; Midazolam; Middle Aged; Pain, Postoperative; Retinal Diseases; Tetrahydronaphthalenes; Treatment Outcome; Vitrectomy

When morphine and dezocine are mixed together, the clinical interactions with analgesic effects and adverse events remain unknown. The authors aimed to investigate the efficacy of low concentrations of dezocine in combination with morphine for postoperative pain.. A prospective, randomized, double-blinded clinical trial.. Cancer Institute and Hospital, National Cancer Center, China.. Sixty patients undergoing thoracotomy were randomized into 3 groups to investigate the analgesic efficacy of different ratios of morphine and dezocine.. The morphine group (Group M) received morphine (1 mg/mL) alone for patient-controlled analgesia (PCA); the morphine+dezocine 1 group (Group MD1) received morphine (1 mg/mL) combined with dezocine (0.05 mg/mL) at a ratio of 20:1 for PCA; the morphine+dezocine 2 group (Group MD2) received morphine (1 mg/mL) combined with dezocine (0.1 mg/mL) at a ratio of 10:1 for PCA. Cumulative morphine consumption, verbal rating scores (VRS), and adverse events were evaluated throughout a 48-hour postoperative period.. Cumulative morphine requirements were (1) statistically higher in Group M than in Group MD2 at 24 and 48 hours after surgery and (2) statistically higher in Group M than Group MD1 at 48 hours after surgery. Postoperative VRS for evaluating pain were similar among the 3 groups. The incidence of postoperative nausea and pruritus was statistically higher in Group M than in Groups MD1 and MD2. The incidence of dizziness was not significantly different among groups.. The combination of morphine and dezocine at the concentrations [morphine (mg/mL)]/[dezocine (mg/mL)] of 1/0.05 (ratio 20:1) and 1/0.1 (ratio 10:1) may enhance postoperative analgesia after thoracotomy.

Topics: Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morphine; Pain, Postoperative; Prospective Studies; Tetrahydronaphthalenes; Thoracotomy

The purpose of the study was to compare the efficacy and adverse events of dezocine with that of fentanyl or placebo for the control of emergence agitation.. 114 children scheduled for adenotonsillectomy under sevoflurane anesthesia were allocated randomly into 1 of the 3 groups to receive dezocine 0.1 mgxkg(-1) (group D, n=38), fentanyl 1 μg×kg(-1) (group F, n=38), or saline (group S, n=38) just before the end of anesthesia. Emergence agitation scores were assessed. Postoperative pain scores, awakening and extubation times, and the incidence of adverse effects were recorded.. Emergence agitation scores, the incidence of emergence agitation and severe emergence agitation were significantly lower in groups D and F than in group S (p=0.021, p=0.018, and p=0.028, respectively). The postoperative pain scores were lower in groups D and F as compared to group S (p=0.01). Awakening and extubation times in groups D and F were longer than that of group S (p=0.001 and p=0.000, respectively). The overall incidence of postoperative complications was higher in group F compared to that in groups D and S (p=0.01).. In children undergoing adenotonsillectomy under sevoflurane anesthesia, a single IV injection of dezocine 0.1 mgxkg(-1) and fentanyl 1 μg×kg(-1) were comparable in decreasing the incidence and severity of emergence agitation. However, the use of dezocine was associated with a lower incidence of postoperative side effects.

Topics: Adenoidectomy; Age Factors; Airway Extubation; Analgesics, Opioid; Anesthetics, Inhalation; Bridged Bicyclo Compounds, Heterocyclic; Child; Child, Preschool; China; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Fentanyl; Humans; Injections, Intravenous; Male; Methyl Ethers; Pain Measurement; Pain, Postoperative; Risk Factors; Sevoflurane; Tetrahydronaphthalenes; Time Factors; Tonsillectomy; Treatment Outcome

To evaluate the efficacy and safety of patient-controlled intravenous analgesia (PCIA) of dezocine combined with sufentanil in burn patients after escharectomy or tangential excision followed by autologous skin grafting.. Sixty burn patients hospitalized in Department of Burns and Plastic Surgery of our hospital from February 2011 to December 2013, conforming to the study criteria and going to have escharectomy or tangential excision followed by autologous skin grafting, were divided into sufentanil group (S, n = 30) and dezocine+sufentanil group (DS, n = 30) according to the random number table. Patients in group S were given 150 mL normal saline containing 2.5 µg/kg sufentanil citrate and 6 mg tropisetron after skin grafting for 48 hours. Patients in group DS were given 150 mL normal saline containing 0.25 mg/kg dezocine, 1.5 µg/kg sufentanil citrate, and 6 mg tropisetron for 48 hours. Visual Analog Scale (VAS), Bruggrmann Comfort Scale (BCS), and Ramsay Sedation Scale were used to evaluate the sedative effect or analgesic effect, and their scores were recorded at administration hour (AH) 2, 6, 12, 24, and 48. The times of efficient injection and incidence of adverse effect within the 48 AH were recorded. Data were processed with analysis of variance for repeated measurement, t test, chi-square test, and Fisher's exact test.. There were no obvious differences in the scores of VAS and BCS between two groups at each time point (with t values from -0.426 to 0.864, P values above 0.05). The scores of Ramsay Sedation Scale in group S at AH 2, 6, 12, 24, and 48 were respectively (3.2 ± 0.6), (3.2 ± 0.5), (3.3 ± 0.7), (3.2 ± 0.4), and (3.3 ± 0.4) points, which were higher than those in group DS [(2.4 ± 0.6), (2.5 ± 0.5), (2.4 ± 0.6), (2.4 ± 0.4), and (2.4 ± 0.5) points, with t values from 5.302 to 8.391, P values below 0.001]. The times of efficient injection within the 48 AH was 6.8 ± 0.7 in group S and 6.5 ± 0.9 in group DS, showing no significantly statistical difference (t = 1.260, P > 0.05). Respiratory depression was not observed in both groups; the incidence of pruritus was the same, and that of urine retention was similar between the 2 groups within the 48 AH (with P values above 0.05). Within the 48 AH, the incidence of nausea and vomiting in group S was 26.7% (8/30), which was obviously higher than that in group DS (6.7%, 2/30, P < 0.05); the incidence of drowsiness in group S was 20.0% (6/30), which was significantly higher than that in group DS (no patient, P < 0.05).. Dezocine combined with sufentanil can provide effective postoperative analgesia with little adverse effect for PCIA in burn patients after escharectomy or tangential excision followed by autologous skin grafting, therefore it can be widely used.

Topics: Analgesia, Patient-Controlled; Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Burns; Female; Humans; Hypnotics and Sedatives; Infusions, Intravenous; Male; Pain, Postoperative; Plastic Surgery Procedures; Skin Transplantation; Sufentanil; Tetrahydronaphthalenes; Treatment Outcome

To evaluate the comparative efficacy and side effect profile of ketorolac 60 mg, dezocine 6 mg, and fentanyl 100 micrograms when used as analgesic supplements to a propofol infusion during monitored anesthesia care (MAC).. Randomized, double-blind, placebo-controlled study.. Ambulatory surgery facility at a university medical center.. 80 outpatients undergoing breast biopsy or inguinal herniorraphy procedures under MAC.. All patients received midazolam 2 mg intravenously (IV) followed by 1 ml of the study medication containing either dezocine 3 mg IV, ketorolac 30 mg IV, fentanyl 50 micrograms IV, or normal saline. A propofol infusion was initiated at 75 micrograms/kg/min and then varied to maintain a stable level of sedation (i.e., Observer Assessment of Alertness/Sedation scale score of 3). An additional 1 ml of the same study medication was administered IV 2 to 3 minutes prior to infiltration of the local anesthetic solution. During the operation, supplemental (rescue) medication consisted of fentanyl 25 micrograms IV, bolus injections in all four treatment groups.. Propofol infusion and supplemental fentanyl dosage requirements, oxygen saturation values, respiratory rates, recovery times, and postoperative side effects were recorded. Visual analog scales were used to assess sedation, anxiety, pain, and nausea preoperatively (baseline), upon entry into the postanesthesia care unit, and at 30-minute intervals until discharge. The fentanyl and dezocine groups required lower average infusion rates of propofol to maintain a stable level of sedation than the control (saline) group. The saline and ketorolac groups required rescue analgesic medication more frequently and/or larger supplemental dosages of fentanyl than the two opioid analgesic treatment groups. Compared with the three analgesic treatment groups, postoperative pain scores were only marginally higher in the control group. Ketorolac-treated patients had consistently (but not significantly) shorter recovery times to oral intake, ambulation, and discharge than those in the dezocine or fentanyl groups. No postoperative nausea, vomiting, or pruritus was reported in the ketorolac group.. Compared with ketorolac 60 mg, fentanyl 100 micrograms and dezocine 6 mg produced a greater decrease in the propofol sedation requirement during MAC. However, the use of ketorolac in combination with propofol for MAC was associated with an improved recovery profile.

Topics: Adult; Ambulatory Surgical Procedures; Analgesics; Analgesics, Opioid; Anesthesia, Local; Bridged Bicyclo Compounds, Heterocyclic; Cycloparaffins; Double-Blind Method; Female; Fentanyl; Humans; Hypnotics and Sedatives; Intraoperative Period; Ketorolac; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Preanesthetic Medication; Propofol; Tetrahydronaphthalenes; Tolmetin

The safety and efficacy of intravenous doses of dezocine (5 or 10 mg), butorphanol (1 mg), and placebo were compared in a double-blind study in 160 patients with moderate to severe postoperative pain. Analgesic efficacy was assessed for 6 hours after each dose. Mean pain relief scores were consistently higher, indicating greater pain relief, for the three active treatment groups than for the placebo group. The 10-mg dezocine dose was the most effective treatment, and 5 mg of dezocine was comparable to 1 mg of butorphanol. In the 2 hours after the first dose, 32% of the 10-mg dezocine group, 53% of the 5-mg dezocine group, 65% of the butorphanol group, and 88% of the placebo group withdrew from the study because of unsatisfactory pain relief. The differences in these percentages were statistically significant (P less than 0.05) between each active therapy group and the placebo group, and between the 10-mg dezocine group and the butorphanol group. Changes in degree of sedation were similar in the three active therapy groups. Adverse reactions were rare, mild, and equally distributed among the four treatment groups. We conclude that 10 mg of dezocine is superior to 1 mg of butorphanol, and that 5 mg of dezocine is as effective as 1 mg of butorphanol for the relief of moderate to severe postoperative pain.

Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Butorphanol; Clinical Trials as Topic; Cycloparaffins; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle Aged; Morphinans; Pain, Postoperative; Placebos; Tetrahydronaphthalenes

Dezocine, a new mixed agonist-antagonist opioid analgesic, and morphine were compared in a double-blind study in 206 patients with postoperative pain. The analgesic efficacy of single intravenous injections of dezocine (2.5, 5.0, and 10.0 mg), morphine (5.0 mg), and placebo was assessed by verbal and visual scales at regular intervals for six hours after administration. All active treatments provided greater pain relief than placebo. Pain relief with dezocine 5 and 10 mg was significantly greater (P less than .05) than with placebo for up to four and five hours, respectively, and with morphine up to one hour. Pain relief scores were significantly higher (P less than .05) with morphine than with placebo at all observations except that of the fifth hour, and higher with dezocine 2.5 mg than with placebo for the first 30 minutes. Doses of 5 and 10 mg of dezocine produced approximately the same peak analgesic effect, with the larger dose having a longer duration of effect. All active treatments produced mild to moderate sedation. Side effects were few and mild or moderate with all of the treatments. The physician's and the patients' evaluations favored dezocine in a dose-dependent order, with morphine 5 mg rated lower than dezocine 5 mg and higher than dezocine 2.5 mg.

Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cycloparaffins; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle Aged; Morphine; Pain, Postoperative; Tetrahydronaphthalenes

The safety and efficacy of single intramuscular doses of dezocine (10 or 15 mg) were compared with butorphanol (2 mg) and placebo in 157 patients with moderate to severe postoperative pain. A verbal pain intensity scale, an analog pain intensity scale, and a verbal pain relief scale were used to record the patients' subjective assessments. The results of this study indicate that a single 10 or 15 mg intramuscular injection of dezocine is safe and more effective than placebo for four to six hours, respectively, in the treatment of moderate to severe postoperative pain (P less than .05). During the first hour of treatment the pain relief afforded by 2 mg of butorphanol was significantly greater than that afforded by 10 mg of dezocine (P less than .05), but both doses of dezocine provided long-lasting relief. The scores on all three efficacy scales were highest with the 15 mg dose of dezocine after the first hour, while the 10 mg dose of dezocine and butorphanol were compared during this period. Nausea and vomiting were the most commonly reported side effects; injection site reactions were reported more frequently in the butorphanol group.

Topics: Acute Disease; Adolescent; Adult; Bridged Bicyclo Compounds, Heterocyclic; Butorphanol; Clinical Trials as Topic; Consumer Behavior; Cycloparaffins; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Morphinans; Nausea; Pain, Postoperative; Placebos; Tetrahydronaphthalenes; Time Factors; Vomiting

Dezocine, a new mixed agonist-antagonist-type opioid analgesic, was compared in a double-blind trial with placebo and 10 mg of morphine in 190 patients with acute postoperative pain. The medications were given intramuscularly. Dezocine was administered at three dose levels (5, 10, and 15 mg). Pain relief scores, sedation, and side effects were recorded at 15, 30, 60, 120 and 240 min after injection. Significantly higher pain relief scores (p less than 0.05) were reported for the groups receiving dezocine 10 and 15 mg than the placebo group at all observation times, except for dezocine 15 mg at four hours. Morphine produced significantly better pain relief than placebo only between the second and fourth hour after administration. Significantly better pain relief was obtained with dezocine (10 and 15 mg) than with morphine during the first hour. The mean four-hour cumulative pain relief scores (TOTPAR) were significantly (p less than 0.05) higher than placebo for all active treatment groups. Side effects were few with no significant differences between the treatment groups. Seventy-nine per cent of the patients in the dezocine 15 mg group, and 73, 68, 58 and 50 per cent respectively, of the patients in the dezocine 10 mg, dezocine 5 mg, morphine 10 mg and placebo group had a satisfactory clinical response. Significantly (p less than 0.05) more patients in the groups receiving dezocine 10 and 15 mg than in the placebo group had a satisfactory clinical response; the difference was not significant for the dezocine 5 mg and morphine 10 mg groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cycloparaffins; Double-Blind Method; Female; Humans; Morphine; Pain, Postoperative; Tetrahydronaphthalenes; Time Factors

The relative performance of three analgesic rating scales--visual pain analog, verbal pain intensity, and verbal pain relief--was assessed in clinical trials with 1,497 patients and a variety of pain models. The scales correlated strongly with one another, with inconsistent and generally minimal differences in sensitivity. Overall, the verbal relief scale tended to be slightly more sensitive than the pain analog rating, which in turn showed a small advantage over the verbal pain intensity assessment. When the scores derived from the categorized ratings 1 hour after drug dosing (generally the time of peak effect) were analyzed, there was little difference whether a parametric or nonparametric approach was taken. When the cumulative measures of overall effect over 6 hours were considered, however, the nonparametric approach was decidedly more powerful. There was a similar pattern when the analog scores were analyzed. This unanticipated finding appears to be due to the cumulative measures (from all three scales) being more skewed toward the lower end of their respective ranges than are the 1-hour scores. A composite efficacy variable was defined, incorporating data from the three primary scales; this measure was found to be generally comparable in sensitivity to the individual scales and may be useful as a global summary of response. While our investigation provides evidence that any of the ratings considered will accurately reflect analgesic response, the verbal relief scale was the most sensitive and might be the best choice if a single measure is desired.

Topics: Bridged Bicyclo Compounds, Heterocyclic; Butorphanol; Clinical Trials as Topic; Cycloparaffins; Double-Blind Method; Humans; Morphinans; Morphine; Pain; Pain, Postoperative; Tetrahydronaphthalenes

We assessed the analgesic effectiveness of a single intramuscular injection of dezocine, 10 mg or 15 mg; morphine, 10 mg; or a placebo in 160 patients with moderate to severe postoperative pain. Dezocine, 10 mg, was as effective as and had approximately the same duration of action as morphine, 10 mg. Dezocine, 15 mg, was more effective than 10 mg of either dezocine or morphine as assessed by three efficacy scales (verbal and analog pain intensity and pain relief), and both drugs were significantly (p less than 0.05) more effective than placebo as assessed by the three efficacy scales and the overall evaluation of the investigator. A small percentage of patients suffered nausea and became sedated; the drugs and placebo, however, did not differ statistically with respect to the side effects. Blood pressure, heart rate, and respiratory rate generally were slightly decreased by both drugs.

Topics: Adult; Aged; Analgesics; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cycloparaffins; Double-Blind Method; Female; Humans; Male; Middle Aged; Morphine; Pain, Postoperative; Random Allocation; Tetrahydronaphthalenes

Dezocine (Wy 16225), a new analgesic was compared randomly and double-blind with morphine 10 mg in 160 female patients complaining of moderate (group I) or severe (group II) pain after elective lower abdominal surgery; both drugs were given i.m. In group I, pain relief with dezocine 10 and 15 mg was significantly greater than dezocine 5 mg; dezocine 10 mg appeared equipotent with morphine 10 mg. Similar, but statistically insignificant differences were observed in group II. Patient sedation was minimal and untoward side-effects infrequent with all doses of the trial drugs.

Topics: Abdomen; Adolescent; Adult; Analgesics; Bridged Bicyclo Compounds, Heterocyclic; Bridged-Ring Compounds; Cesarean Section; Clinical Trials as Topic; Cycloparaffins; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Morphine; Pain, Postoperative; Pregnancy; Tetrahydronaphthalenes

In a population of 61 surgical patients, 10 and 15 mg dezocine were compared with meperidine 100 mg for relief of postoperative pain. Pain relief experienced by the patient and pain intensity evaluated by a nurse and a physician displayed similar characteristics: dezocine 10 mg was less effective than meperidine but dezocine 15 mg showed a rapid onset of analgesic effect with a longlasting analgesia superior to meperidine. Vital signs remained stable within satisfactory limits with no respiratory depression occurring. Blood-gas analysis showed a significant but comparable increase in PaCO2 with slight decrease of PaO2 in all patients treated with dezocine or meperidine. Side effects observed included an overt sedative effect of both analgesics, which for dezocine appeared to be dose-related.

Topics: Adolescent; Adult; Aged; Analgesics; Blood Gas Analysis; Bridged Bicyclo Compounds, Heterocyclic; Bridged-Ring Compounds; Clinical Trials as Topic; Cycloparaffins; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Meperidine; Middle Aged; Pain, Postoperative; Respiration; Tetrahydronaphthalenes; Time Factors

The relieving role of dezocine in pain after surgery was previously reported, while the potential mechanism was not completely clear. Therefore, the current research probed into the regulatory mechanism of dezocine in pain after surgery. A postoperative pain model was established by performing plantar incision surgery on the juvenile Sprague-Dawley rats. After the rats were treated with dezocine or SC79 (Akt1 activator), the paw withdrawal threshold and paw withdrawal latency of rats were detected to evaluate the mechanical allodynia and thermal hyperalgesia. After the plantar tissue, dorsal root ganglions, and spinal cord of rats were collected, the expressions of Akt1, p-Akt1, GSK-3β, and p-GSK-3β in the tissues were determined by western blot to evaluate the activation state of the Akt1/GSK-3β pathway. After surgery, the paw withdrawal threshold and paw withdrawal latency of rats were lessened, whereas the ratios of p-Akt1/Akt1 and p-GSK-3β/GSK-3β were augmented in rat plantar tissue, dorsal root ganglions, and spinal cord. After treatment with dezocine alone, the paw withdrawal threshold and paw withdrawal latency of postoperative rats were elevated, but ratios of p-Akt1/Akt1 and p-GSK-3β/GSK-3β were reduced. After co-treatment with dezocine and SC79, SC79 reversed the effects of dezocine on elevating the paw withdrawal threshold and paw withdrawal latency, and reducing the ratios of p-Akt1/Akt1 and p-GSK-3β/GSK-3β in postoperative rats. Dezocine ameliorated the postoperative hyperalgesia in rats via repressing the hyper-action of Akt1/GSK-3β pathway.

Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Glycogen Synthase Kinase 3 beta; Hyperalgesia; Pain, Postoperative; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes

Cancer is the second leading cause of death following ischemic heart disease in the world and the primary clinical, social and economic burden. Surgical resection is the main measure for the treatment of the vast majority of solid tumors. However, the recurrence and metastasis of tumors occur at different periods after surgery in many cases undergoing radical tumor surgery, which is the main cause of death of tumor patients. Moreover, tumor patients are prone to suffer from mental depression, which may increase the morbidity and mortality of tumors. Tumors have a series of clinical biological signs with the following five main features: postoperative pain and cancerous pain; suppression of antitumor immunity; angiogenesis in tumors; proliferation, growth and metastasis of tumors; and mental depression. Surgery is the first treatment in the majority of cancer patients with solid tumors. Opioids are required for anesthesia and postoperative analgesia. For cancerous pain control, patients undergo surgery, and their quality of life of is improved. However, traditional opioids, such as morphine, may inhibit antitumor immunity, induce vascular growth of tumors and promote the proliferation, invasion and migration of cancer cells, and traditional opioids can induce a risk of somatic dependence. However, studies have found that not all opioids share the effects of immunosuppression, tumor proliferation promotion and angiogenesis induction. Dezocine, a novel opioid with specific pharmacological mechanisms, has been demonstrated to regulate the five clinical and biological features of tumors. We reviewed the preclinical and clinical studies of dezocine on postoperative pain and cancer pain in tumor patients as well as the immune system, tumor angiogenesis, tumor proliferation, tumor growth, tumor metastasis and mental depression. We proposed that dezocine may be the best choice of opioids for anesthesia and analgesia in cancer patients.

Topics: Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Cancer Pain; Humans; Neoplasms; Pain, Postoperative; Quality of Life; Tetrahydronaphthalenes

It is very important for breast cancer patients undergoing surgery to choose an opioid that has little effect on the immune system. The aim of this study is to compare the effects of dezocine or sufentanil on postoperative pain and Th1/Th2 balance in patients undergoing breast cancer surgery.. Data from 92 breast cancer patients from January 2019 to July 2020 at Foshan Second People's Hospital (Guangdong, China) were analyzed. Sufentanil (SF) was used in group SF (n = 44) and dezocine (DE) in group DE (n = 48). The Visual Analog Scale (VAS) scores were assessed, and the percentages of Th1 cells and Th2 cells in peripheral blood were detected before anesthesia and at 2, 12, 24, and 48 hours after surgery.. There was no significant difference in the VAS scores between the two groups at 2, 24, and 48 hours after surgery (P > 0.05). The VAS scores at 12 hours after surgery in group DE were significantly lower than those in group SF with a statistically significant difference (P < 0.05). The percentage of Th1 cells in group DE at 2, 12, 24, and 48 hours after surgery was significantly lower than that in group SF (P < 0.05). The percentage of Th2 cells in group DE at 2, 12, 24, and 48 hours after surgery was significantly lower than that in group SF (P < 0.05). The Th1/Th2 ratio at 2, 12, 24, and 48 hours after surgery was significantly higher in group DE than that in group SF (P < 0.05).. Dezocine for anesthesia induction and postoperative analgesia can maintain the balance of Th1/Th2 more stable than, with the same analgesia efficacy as, sufentanil during the early postoperative period in breast cancer patients undergoing surgery.

Topics: Adult; Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Analgesics, Opioid; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; China; Female; Humans; Injections, Intravenous; Middle Aged; Pain Management; Pain, Postoperative; Postoperative Period; Sufentanil; Tetrahydronaphthalenes

Topics: Analgesics, Opioid; Animals; Bridged Bicyclo Compounds, Heterocyclic; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Hippocampus; Hyperalgesia; Male; Mice, Inbred ICR; Pain, Postoperative; Phosphorylation; Postoperative Period; Remifentanil; Spinal Cord; Tetrahydronaphthalenes

At present, the drugs used in the field of postoperative analgesia are mainly opioids. The three analgesics selected in this study are opioid receptor agonists, but opioids are easy to produce adverse reactions. In this study, the visual analogue score of resting pain and dynamic pain at two time points of 4 hours and 12 hours was observed in group B and group C were higher than that in group A (P<0.05), indicating that the analgesic effect of dezocine was better. Follow up observation of adverse reactions, dezocine group patients had fewer adverse reactions (P<0.05). It can be seen that although there are certain differences in the mechanism of these three drugs, there are some relevant evidence that all three drugs can be used safely and effectively for postoperative obstetric analgesia.

Topics: Adult; Analgesics; Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Butorphanol; Cesarean Section; Female; Humans; Male; Pain Measurement; Pain, Postoperative; Pregnancy; Tetrahydronaphthalenes; Tramadol

The aim of this study was to evaluate oxycodone versus dezocine for postoperative analgesia in patients with cervical cancer treated with radical surgery.. Fifty-one cases of cervical cancer treated with radical surgery were included in the present study and divided into oxycodone group (n = 26) and dezocine group (n = 25). Patients in the oxycodone group were given with oxycodone 1 mg/kg plus tropisetron 0.1 mg/kg diluting to 100 ml by 0.9% saline for patient-controlled intravenous analgesia (PCIA) after surgery. Moreover, patients in the dezocine group were given with dezocine 0.6 mg/kg plus tropisetron 0.1 mg/kg diluting to 100 ml by 0.9% saline for PCIA after surgery. The visual analog scale (VAS) and Ramsay sedation score of the two groups were recorded in the time point of 4, 8, 12, 24, and 48 h after surgery. The adverse event-related drugs were recorded and compared between the two groups.. The VAS score was significantly lower in oxycodone group compared to dezocine group in the time point of 4, 8, 12, 24, and 48 h (Pall < 0.05). The Ramsay score at time point of 4, 8, 12, 24 h, and 48 h were obviously higher in oxycodone group than those in dezocine group (P < 0.05) which indicated that the sedative effect in oxycodone group was superior to dezocine. For oxycodone group, there were six cases (23.08%) with nausea and one case (3.85) with vomiting in the treatment procedure. Moreover, for dezocine group, there were one case (4.00%) with nausea, two cases (8.00%) with vomiting, and two cases (8.00%) with dizzy in the treatment procedure. There was no statistical difference of adverse event risk between the two groups (P > 0.05).. Oxycodone postoperative analgesia is superior to dezocine for patients with cervical cancer treated with radical surgery.

Topics: Analgesics, Opioid; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Oxycodone; Pain Measurement; Pain, Postoperative; Tetrahydronaphthalenes; Treatment Outcome; Uterine Cervical Neoplasms

Topics: Analgesics; Bridged Bicyclo Compounds, Heterocyclic; Butorphanol; Cycloparaffins; Humans; Morphinans; Pain, Postoperative; Tetrahydronaphthalenes